Delving into the Latest Updates on RDC Clinical Pty Ltd with Synapse

A Randomized, Double-blind Placebo-controlled Study in Healthy Subjects to Compare the Bioavailability of EPA + DHA from Two Microalgal Sources to One Fish Source

This is a randomised, double-blind placebo-controlled study in healthy subjects to compare the absorption of two microalgal formulations, to a fish oil and a placebo.

开始日期2025-01-01

申办/合作机构

RDC Clinical Pty Ltd

NCT06006416 / Withdrawn临床3期

Effect of Fenugreek Fibre (Trigonella Foenum-graecum) on the Gut Microbiome in an Adult Population - an Open Label, Self-controlled Trial

A open label, self-controlled trial to evaluate the effect of Fenugreek Fibre (Trigonella foenum-graecum) on the gut microbiome in generally healthy adults aged 18-65 years old.

开始日期2024-12-01

申办/合作机构

RDC Clinical Pty Ltd

NCT06444763 / Not yet recruiting临床3期

Effect of Maolactin™ FMR Supplementation on Exercise Recovery, Inflammation, and Muscle Comfort in an Otherwise Healthy Population: a Double-blind Randomized Placebo-controlled Study

This is a double blind, randomised, placebo-controlled, parallel-group trial to evaluate the effect of Maolactin FMR supplementation on chronic inflammation, mobility and muscle and joint pain in an otherwise healthy population of adults 45-65 years old over 14 weeks with 12 weeks supplementation.
This is PART B of the study.

开始日期2024-11-15

申办/合作机构

RDC Clinical Pty Ltd

100 项与 RDC Clinical Pty Ltd 相关的临床结果

登录后查看更多信息

0 项与 RDC Clinical Pty Ltd 相关的专利（医药）

登录后查看更多信息

20

项与 RDC Clinical Pty Ltd 相关的文献（医药）

2023-01-01·Frontiers in sports and active living

Libifem® (Trigonella foenum-graecum) in conjunction with exercise on muscle strength, power, endurance, and body composition in females aged between 25 and 45 years.

Article

作者: Clayton, Paul ; Rao, Amanda ; Briskey, David

IntroductionThis study examined the effects of Libifem® on exercise performance and body composition in females 25-45 years old.MethodsParticipants were randomized to three equal groups to consume: 600 mg Libifem®/day, 300 mg Libifem®/day or a placebo for 8 weeks. Participants completed a whole-body exercise program three times a week for 8 weeks. At baseline, week 4 and week 8, muscle strength and endurance, functional threshold power, body composition, and sex hormones were measured. At week 8, all three groups increased leg press 1RM compared to baseline.ResultsA significant difference between group treatment effect was seen for leg press at week 8 (p = 0.045), with the 600 mg Libifem® group significantly increasing their leg press 1RM compared to placebo (p = 0.014). The 600 mg Libifem® group significantly reduced their total fat mass (0.96 kg loss) from baseline compared to placebo group (0.09 kg gain). There was no significant difference in fat mass for the 300 mg Libifem® group (0.23 kg loss). The 600 mg Libifem® group had a significant increase in lean mass compared to both the 300 mg and placebo groups (p = 0.011 and 0.009, respectively).DiscussionOverall, there were significant and dose-related changes in body composition and ergogenic parameters, comparable with previous findings in males.Clinical Trial RegistrationThis trial was registered with the Australian and New Zealand Clinical Trials registry [ACTRN12618001538235].

2023-01-01·Skin Pharmacology and Physiology

Efficacy of Topical Palmitoylethanolamide (Levagen+) for the Management of Eczema Symptoms: A Double-Blind, Comparator-Controlled, Randomized Clinical Trial

Article

作者: Briskey, David ; Rao, Amanda ; Moussa, Amel A ; Erickson, Jane

Introduction: Eczema is a debilitating skin disorder clinically characterised by the development of itchy, dry, rough, and scaling skin caused by a series of rudimentary clinical phenotypes. Methods: This double-blind, randomised, comparator-controlled trial evaluated the effectiveness of topical application of a novel palmitoylethanolamide formulation (Levagen+) compared with a standard moisturiser (comparator) to reduce eczema severity and improve patient outcomes. Seventy-two participants aged over 18 years old with atopic eczema (symptoms including redness, dry skin, scaling, and/or itchiness) on their hands or arm were recruited. Participants were randomly allocated to one of two treatment groups (Levagen + or comparator). Treatment was applied to the affected area twice daily for 4 weeks. Outcome measures included Self-Assessed Eczema Area Severity Index (SA-EASI) scoring and Patient-Oriented Eczema Measure (POEM) from baseline to week 4. Results: Levagen+ was effective at alleviating symptom severity of eczema over 4 weeks. Levagen+ significantly reduced redness, dryness, and total POEM score compared to a comparator cream. Conclusion: Levagen+ can significantly reduce eczema symptom severity compared to a comparator product, supporting its use as a potential treatment for eczema. Trial registration: <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov" xmlns:xlink="http://www.w3.org/1999/xlink">clinicaltrials.gov</ext-link> Identifier: NCT05003453.

2023-01-01·Food and Nutrition Sciences

Efficacy of InferrinTM and Lactoferrin on Symptoms of Irritable Bowel Syndrome in Otherwise Healthy Adults: A Randomised, Double-Blind, Placebo-Controlled Study

作者: Rao, Amanda ; Briskey, David

Irritable bowel syndrome affects one in five Australians, with abdominal pain as one of the main symptoms.Lactoferrin, found in milk, is known for its anti-inflammatory properties, and the development of a novel microencapsulated form, Inferrin, may be useful in the treatment of irritable bowel syndrome symptoms.The current study aimed to study the effectiveness of Inferrin compared to lactoferrin and a placebo on irritable bowel syndrome symptoms.Sixty-eight male and female participants over 18 years of age were recruited to complete 8 wk of supplementation with either Inferrin, lactoferrin, or a matched placebo.Outcomes were measured at baseline, week 4, and week 8.There was a decrease from baseline across all groups in IBS symptom severity at weeks 4 and 8, as well as improvements in QOL scores.Lactoferrin and Inferrin groups had a significant reduction from baseline to week 8 in weekly stool frequency.Overall, lactoferrin and Inferrin appeared to have an effect in decreasing symptoms of IBS and weekly stool frequency.

100 项与 RDC Clinical Pty Ltd 相关的药物交易

登录后查看更多信息

100 项与 RDC Clinical Pty Ltd 相关的转化医学

登录后查看更多信息